VCYT Veracyte Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VCYT

Price (delayed)

$22.43

Market cap

$1.62B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.51

Enterprise value

$1.48B

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other ...

Highlights
The EPS has surged by 54% year-on-year and by 14% since the previous quarter
Veracyte's net income has surged by 52% YoY and by 15% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.veracyte.com
Peers: EXAS BIOC MYGN

Key stats

What are the main financial stats of VCYT
Market
Shares outstanding
72.15M
Market cap
$1.62B
Enterprise value
$1.48B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.5
Price to sales (P/S)
5.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.98
Earnings
Revenue
$296.54M
EBIT
-$36.43M
EBITDA
-$7.18M
Free cash flow
-$1.01M
Per share
EPS
-$0.51
Free cash flow per share
-$0.01
Book value per share
$14.98
Revenue per share
$4.14
TBVPS
$3.99
Balance sheet
Total assets
$1.16B
Total liabilities
$81.22M
Debt
$14.72M
Equity
$1.08B
Working capital
$186.02M
Liquidity
Debt to equity
0.01
Current ratio
3.97
Quick ratio
3.57
Net debt/EBITDA
19.54
Margins
EBITDA margin
-2.4%
Gross margin
65.7%
Net margin
-12.3%
Operating margin
-13.9%
Efficiency
Return on assets
-3.2%
Return on equity
-3.4%
Return on invested capital
-51.8%
Return on capital employed
-3.3%
Return on sales
-12.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VCYT stock price

How has the Veracyte stock price performed over time
Intraday
-3.78%
1 week
6.35%
1 month
-11.9%
1 year
-18.61%
YTD
-5.48%
QTD
-5.48%

Financial performance

How have Veracyte's revenue and profit performed over time
Revenue
$296.54M
Gross profit
$194.95M
Operating income
-$41.08M
Net income
-$36.56M
Gross margin
65.7%
Net margin
-12.3%
The net margin has soared by 64% YoY and by 19% from the previous quarter
The operating margin has soared by 63% YoY and by 18% from the previous quarter
Veracyte's net income has surged by 52% YoY and by 15% QoQ
The operating income has grown by 50% YoY and by 14% from the previous quarter

Growth

What is Veracyte's growth rate over time

Valuation

What is Veracyte stock price valuation
P/E
N/A
P/B
1.5
P/S
5.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.98
The EPS has surged by 54% year-on-year and by 14% since the previous quarter
The P/B is 69% below the 5-year quarterly average of 4.9
The equity has grown by 2.6% from the previous quarter
The P/S is 50% below the 5-year quarterly average of 10.8 and 7% below the last 4 quarters average of 5.8
Veracyte's revenue has increased by 35% YoY and by 4.6% QoQ

Efficiency

How efficient is Veracyte business performance
The return on sales has surged by 67% year-on-year and by 21% since the previous quarter
VCYT's return on invested capital has surged by 64% year-on-year and by 25% since the previous quarter
The company's return on equity has surged by 53% YoY and by 15% QoQ
The ROA has soared by 53% YoY and by 14% from the previous quarter

Dividends

What is VCYT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VCYT.

Financial health

How did Veracyte financials performed over time
The total liabilities has contracted by 11% YoY but it has grown by 4.4% from the previous quarter
The company's current ratio rose by 4.7% YoY but it fell by 2.9% QoQ
The debt is 99% less than the equity
VCYT's debt to equity has dropped by 50% since the previous quarter and by 50% year-on-year
The debt has contracted by 22% YoY and by 12% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.